In this article, we will discuss Golimumab and Infections. So, let’s get started.
Golimumab and Infections
In controlled Phase 3 trials through Week 16 in RA, PsA, and AS, infections were observed in 28% of Golimumab-treated patients compared to 25% of control-treated patients.